Navigation Links
CT and serum LDH shows promise as survival predictor for some metastatic melanoma patients
Date:4/16/2013

Combining CT imaging findings with baseline serum lactate dehydrogenase levels is showing promise as a way to predict survival in patients with metastatic melanoma being treated with anti-angiogenic therapy.

With the hope of predicting patient survival, researchers at the University of Mississippi Medical Center in Jackson and at the Ohio State University Comprehensive Cancer Center in Columbus analyzed CT images and clinical data from 46 patients with metastatic melanoma that were treated with anti-angiogenic therapy. "The analysis found that initial post-therapy CT imaging changes in tumor morphology, attenuation, size and structure (MASS Criteria) are predictive of survival. These results are similar to what we have found in patients with metastatic kidney cancer, another highly vascular tumor treated with anti-angiogenic therapy. The current study is the first of its kind to associate CT findings of tumor devascularization with survival in patients with metastatic melanoma treated with anti-angiogenic therapy," said Dr. Andrew Smith of the University of Mississippi.

"Patients with high baseline serum lactate dehydrogenase (LDH) tend to have poor overall survival compared to patients with low serum LDH," said Dr. Smith. LDH levels are used to stage metastatic melanoma, but are only weakly associated with survival when used alone," he said. "What was surprising to us was that the accuracy for predicting both progression-free and overall survival is substantially increased when MASS Criteria findings are combined with data from serum LDH levels," said Dr. Smith.

"This was an exploratory study," said Dr. Smith. "The next step is to take what we've discovered and test it in prospective clinical trials. At a minimum, patients with low baseline serum LDH and evidence of tumor devascularization on their initial post-therapy CT should be encouraged that they are likely to have a favorable response to therapy," he said.

"The hope is to identify patients that will best respond to anti-angiogenic therapy so we can improve their survival and quality of life. Patients identified as nonresponders could be offered alternative treatments to avoid unnecessary drug toxicities and cost from a therapy that will not improve their survival or quality of life," he said.

Dr. Smith's study will be presented April 17 during the ARRS Annual Meeting in Washington, DC.


'/>"/>

Contact: Samantha Schmidt
sschmidt@arrs.org
703-858-4316
American Roentgen Ray Society
Source:Eurekalert

Related medicine news :

1. Low levels of serum bilirubin spell higher lung cancer risk for male smokers
2. New - Renaissance Age Serum, a Revival in Swiss Anti-Aging Skin Care; Improve Skin Texture for a More Youthful Appearance using Gerda Spillmann’s Newest Anti-Aging Serum
3. Some minorities believe they are less likely to get cancer compared to whites, Moffitt study shows
4. Study shows severity of sleep apnea is influenced by race
5. Stanford study shows different brains have similar responses to music
6. 2-drug combo more effective in treating sarcomas, Moffitt Cancer Center study shows
7. Experimental Vaccine Shows Promise for Ovarian Cancer
8. 2-step ovarian cancer immunotherapy made from patients own tumor shows promise
9. CAMH study shows mental illness associated with heavy cannabis use
10. More Evidence Shows Hormone Therapy May Increase Breast Cancer Risk
11. New technique shows promise in restoring near vision without glasses
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... , ... March 23, 2017 ... ... financial services firm serving the families and businesses of the Norwalk and ... program. Northern Ohio Recovery Center (N.O.R.A.) is a nonprofit, community-based substance abuse ...
(Date:3/23/2017)... ... March 23, 2017 , ... Hakim ... based healthcare technology company California Healthcom Group (CHG). , The HUG investment ... arena. With headquarters in California, CHG is a growing, internationally recognized healthcare management, ...
(Date:3/23/2017)... ... 2017 , ... March 23, 2017 - Crawford Technologies announced ... customer invoices, bills, statements and other correspondence when they have been lost or ... and print the documents and batch them for efficient handling. , Many ...
(Date:3/23/2017)... MIAMI, Fla. (PRWEB) , ... March 23, 2017 ... ... company transforming healthcare for seniors, today announced rapid completion of the strategic executive ... to announce several notable additions to the ChenMed executive team,” says Christopher Chen, ...
(Date:3/23/2017)... PA (PRWEB) , ... March 23, 2017 , ... It’s ... That means many students are thinking about summer internships , which can be ... thereof). , The pros at Garden Media Group, a boutique public relations firm outside ...
Breaking Medicine News(10 mins):
(Date:3/23/2017)... SAO PAULO , March 23, 2017 ... accordance with article 157, paragraph 4 of Law 6,404/76 ... Commission (CVM), hereby informs its shareholders and the market ... jointly with its subsidiary Centro de Diagnosticos por Imagem ... acquisition of 100% interest in RADIOLOGISTAS ASSOCIADOS LTDA. (" ...
(Date:3/23/2017)... , March 23, 2017 Ascendis Pharma ... innovative TransCon technology to address significant unmet medical needs ... host a conference call and webcast on Monday, April ... Endocrine Society in Orlando, Florida , ... pipeline candidates (TransCon Growth Hormone, TransCon PTH and TransCon ...
(Date:3/23/2017)... , March 23, 2017 /PRNewswire/ - INVICTUS MD STRATEGIES ... FRA: 8IS) Invictus MD announces that AB Laboratories Inc. ... its licensed production facility under the Access to Cannabis ... Hamilton, Ontario . The facility, ... October 2016, is currently operating at half capacity, with ...
Breaking Medicine Technology: